Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

Higher working memory predicts slower functional decline in autopsy-confirmed Alzheimer's disease.

Pillai JA, Bonner-Jackson A, Walker E, Mourany L, Cummings JL.

Dement Geriatr Cogn Disord. 2014;38(3-4):224-33. doi: 10.1159/000362715. Epub 2014 Jun 4.

2.

Faster cognitive and functional decline in Dysexecutive versus amnestic Alzheimer's subgroups: a longitudinal analysis of the National Alzheimer's Coordinating Center (NACC) database.

Mez J, Cosentino S, Brickman AM, Huey ED, Manly JJ, Mayeux R.

PLoS One. 2013 Jun 3;8(6):e65246. doi: 10.1371/journal.pone.0065246. Print 2013.

3.

Impact of Alzheimer's Disease, Lewy Body and Vascular Co-Pathologies on Clinical Transition to Dementia in a National Autopsy Cohort.

Pillai JA, Butler RS, Bonner-Jackson A, Leverenz JB.

Dement Geriatr Cogn Disord. 2016;42(1-2):106-16. doi: 10.1159/000448243. Epub 2016 Sep 14.

4.

Comparing measures of decline to dementia in amnestic MCI subjects in the National Alzheimer's Coordinating Center (NACC) Uniform Data Set.

Monsell SE, Liu D, Weintraub S, Kukull WA.

Int Psychogeriatr. 2012 Oct;24(10):1553-60. doi: 10.1017/S1041610212000452. Epub 2012 Apr 16.

5.

Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both.

Kraybill ML, Larson EB, Tsuang DW, Teri L, McCormick WC, Bowen JD, Kukull WA, Leverenz JB, Cherrier MM.

Neurology. 2005 Jun 28;64(12):2069-73.

6.

Progression of Alzheimer's disease during a three-year follow-up using the CERAD-NB total score: Kuopio ALSOVA study.

Hallikainen I, Hänninen T, Fraunberg M, Hongisto K, Välimäki T, Hiltunen A, Karppi P, Sivenius J, Soininen H, Koivisto AM; ALSOVA study group.

Int Psychogeriatr. 2013 Aug;25(8):1335-44. doi: 10.1017/S1041610213000653. Epub 2013 May 16.

PMID:
23676340
7.

Functional assessment staging (FAST) in Korean patients with Alzheimer's disease.

Na HR, Kim SY, Chang YH, Park MH, Cho ST, Han IW, Kim TY, Hwang SA.

J Alzheimers Dis. 2010;22(1):151-8. doi: 10.3233/JAD-2010-100072.

PMID:
20847407
8.

Regional functional connectivity predicts distinct cognitive impairments in Alzheimer's disease spectrum.

Ranasinghe KG, Hinkley LB, Beagle AJ, Mizuiri D, Dowling AF, Honma SM, Finucane MM, Scherling C, Miller BL, Nagarajan SS, Vossel KA.

Neuroimage Clin. 2014 Jul 23;5:385-95. doi: 10.1016/j.nicl.2014.07.006. eCollection 2014.

9.

Rate of progression differs in frontotemporal dementia and Alzheimer disease.

Rascovsky K, Salmon DP, Lipton AM, Leverenz JB, DeCarli C, Jagust WJ, Clark CM, Mendez MF, Tang-Wai DF, Graff-Radford NR, Galasko D.

Neurology. 2005 Aug 9;65(3):397-403.

PMID:
16087904
10.

Cognitive and Functional Decline in Patients With Mild Alzheimer Dementia With or Without Comorbid Diabetes.

Ascher-Svanum H, Chen YF, Hake A, Kahle-Wrobleski K, Schuster D, Kendall D, Heine RJ.

Clin Ther. 2015 Jun 1;37(6):1195-205. doi: 10.1016/j.clinthera.2015.01.002. Epub 2015 Feb 9.

11.

Trajectories of cognitive decline in different types of dementia.

Smits LL, van Harten AC, Pijnenburg YA, Koedam EL, Bouwman FH, Sistermans N, Reuling IE, Prins ND, Lemstra AW, Scheltens P, van der Flier WM.

Psychol Med. 2015 Apr;45(5):1051-9. doi: 10.1017/S0033291714002153. Epub 2014 Sep 17.

PMID:
25229325
12.

A 2-year follow-up of 233 very mild (CDR 0.5) Alzheimer's disease patients (REAL.FR cohort).

Nourhashémi F, Ousset PJ, Gillette-Guyonnet S, Cantet C, Andrieu S, Vellas B; REAL.FR cohort.

Int J Geriatr Psychiatry. 2008 May;23(5):460-5.

PMID:
17894422
13.
14.

Neuropsychological changes in asymptomatic persons with Alzheimer disease neuropathology.

Monsell SE, Mock C, Hassenstab J, Roe CM, Cairns NJ, Morris JC, Kukull W.

Neurology. 2014 Jul 29;83(5):434-40. doi: 10.1212/WNL.0000000000000650. Epub 2014 Jun 20.

15.

Longitudinal Neuropsychological Outcome in Taiwanese Alzheimer's Disease Patients Treated with Medication.

Yang YH, Wu MN, Chou PS, Su HC, Lin SH, Sung PS.

Curr Alzheimer Res. 2018 Mar 14;15(5):474-481. doi: 10.2174/1567205014666171010112518.

PMID:
29032750
16.

Differences in rate of functional decline across three dementia types.

Gill DP, Hubbard RA, Koepsell TD, Borrie MJ, Petrella RJ, Knopman DS, Kukull WA.

Alzheimers Dement. 2013 Oct;9(5 Suppl):S63-71. doi: 10.1016/j.jalz.2012.10.010. Epub 2013 May 2.

17.

Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.

Wilcock GK, Black SE, Hendrix SB, Zavitz KH, Swabb EA, Laughlin MA; Tarenflurbil Phase II Study investigators.

Lancet Neurol. 2008 Jun;7(6):483-93. doi: 10.1016/S1474-4422(08)70090-5. Epub 2008 Apr 29. Erratum in: Lancet Neurol. 2011 Apr;10(4):297. Lancet Neurol. 2008 Jul;7(7):575.

PMID:
18450517
18.

Cognitive decline is faster in Lewy body variant than in Alzheimer's disease.

Olichney JM, Galasko D, Salmon DP, Hofstetter CR, Hansen LA, Katzman R, Thal LJ.

Neurology. 1998 Aug;51(2):351-7.

PMID:
9710002
19.

Revised criteria for mild cognitive impairment may compromise the diagnosis of Alzheimer disease dementia.

Morris JC.

Arch Neurol. 2012 Jun;69(6):700-8. doi: 10.1001/archneurol.2011.3152.

20.

Patterns of Cognitive Decline Prior to Dementia in Persons with Mild Cognitive Impairment.

Cloutier S, Chertkow H, Kergoat MJ, Gauthier S, Belleville S.

J Alzheimers Dis. 2015;47(4):901-13. doi: 10.3233/JAD-142910.

Supplemental Content

Support Center